CELLMOSAIC, INC.

CELLMOSAIC, INC. specializes in the precision synthesis of complex chemical compounds for translational research and diagnostic applications, with deep expertise in small-molecule manufacturing under Good Manufacturing Practices (GMP) and research-grade protocols. The company delivers custom-synthesized compounds for high-impact biomedical programs, particularly those supporting early-stage drug discovery and in vitro diagnostic development. Their technical capabilities encompass organic synthesis, purification, analytical characterization, and scalable production of novel chemical entities—critical for accelerating preclinical translation in academic and federal research environments. A key differentiator is their ability to rapidly respond to dynamic research needs with high-purity, structurally complex molecules, often under tight timelines for NIH-funded initiatives. CELLMOSAIC, INC. maintains a focused and trusted relationship with the Department of Health and Human Services, primarily supporting the National Center for Advancing Translational Sciences (NCATS) through the Early Translation Branch. Their work involves synthesizing proprietary chemical probes and diagnostic precursors that enable target validation, assay development, and mechanistic studies in disease models. This recurring engagement reflects a strong alignment with HHS’s mission to bridge laboratory discoveries and clinical applications. The contractor’s primary industry focus lies in in vitro diagnostic substance manufacturing and specialized chemical synthesis, serving the biopharmaceutical and translational research sectors. They operate at the intersection of medicinal chemistry and diagnostic development, supplying critical reagents that underpin next-generation diagnostics and therapeutic screening platforms. Their market positioning is that of a nimble, high-precision supplier to government-funded innovation pipelines. As a woman-owned small business based in Woburn, Massachusetts, CELLMOSAIC, INC. brings agility and regulatory rigor to federal R&D supply chains. Their certifications include Woman-Owned Business status, reinforcing their commitment to diversity in federal contracting while maintaining compliance with quality systems essential for biomedical manufacturing.